ArticleThe journal of liquid biopsy2026
Concordance of tumor-informed and tumor-agnostic ctDNA assays for treatment response monitoring in advanced solid tumors.
Article in The journal of liquid biopsy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating tumor DNA (ctDNA), obtained serially during cancer treatment, can capture tumor burden trends to help interpret response and detect resistance to systemic therapy for patients with advanced disease. Traditionally, tumor-informed assays track somatic variants identified from an initial tumor biopsy and have demonstrated prognostic utility for early-stage disease. However, tumor-informed ctDNA assays are potentially limited by logistical and methodologic considerations in the setting of advanced disease. In contrast, methylation-based tumor-agnostic assays offer an alternative approach, interrogating thousands of differentially methylated regions that are broadly shared across cancer cells, without requiring a bespoke panel. A comparison of the two approaches for monitoring ctDNA in advanced cancer is lacking. In this study, a head-to-head comparison was performed between commercially available tumor-agnostic and tumor-informed ctDNA assays. The quantitative correlation of ctDNA between the two assays was determined to be high (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.